A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain

Celgene706 enrolled

Overview

This is an observational, post-authorization, retrospective, multicenter study (PAS-OD) that will be conducted in approximately 20 centers in Spain. In all cases, only data recorded prior to the date of study start will be collected to ensure its retrospective nature, thus reflecting real clinical practice, avoiding any influence on the physician's clinical practice.

Study Type

OBSERVATIONAL

Enrollment

706

Conditions

Multiple Myeloma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged ≥ 18 years * Patients with newly diagnosed MM who were not suitable candidates for ASCT who started anti-myeloma treatment between 2012 and 2016, inclusive. * Patients who give informed consent before data collection begins. Exclusion Criteria: * Patients who participated in a clinical trial for first-line treatment of MM during the study period. * Patients who are alive, but do not give their IC. * Patients with MM who did not receive treatment.

Locations (20)

H. Santiago (CHUS)

Santiago de Compostela, A Coruña, Spain

H. Txagorritxu

Vitoria-Gasteiz, Alava, Spain

Outcomes

Primary Outcomes

Description of the first-line treatment regimens

Number of patients in the different first-line treatment regimens, in terms of the main drug used in patients diagnosed de novo with MM who were not candidates for autologous stem cell transplantation (ASCT)